398 related articles for article (PubMed ID: 25860576)
21. Perspectives of gene therapy for primary immunodeficiencies.
Chinen J; Puck JM
Curr Opin Allergy Clin Immunol; 2004 Dec; 4(6):523-7. PubMed ID: 15640693
[TBL] [Abstract][Full Text] [Related]
22. Gene therapy of severe combined immunodeficiencies.
Cavazzana-Calvo M; Hacein-Bey S; Yates F; de Villartay JP; Le Deist F; Fischer A
J Gene Med; 2001; 3(3):201-6. PubMed ID: 11437325
[TBL] [Abstract][Full Text] [Related]
23. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
[TBL] [Abstract][Full Text] [Related]
24. Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases.
Candotti F
Int J Hematol; 2014 Apr; 99(4):383-92. PubMed ID: 24488786
[TBL] [Abstract][Full Text] [Related]
25. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.
Huston MW; van Til NP; Visser TP; Arshad S; Brugman MH; Cattoglio C; Nowrouzi A; Li Y; Schambach A; Schmidt M; Baum C; von Kalle C; Mavilio F; Zhang F; Blundell MP; Thrasher AJ; Verstegen MM; Wagemaker G
Mol Ther; 2011 Oct; 19(10):1867-77. PubMed ID: 21750532
[TBL] [Abstract][Full Text] [Related]
26. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
[TBL] [Abstract][Full Text] [Related]
27. Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.
Montiel-Equihua CA; Thrasher AJ; Gaspar HB
Curr Gene Ther; 2012 Feb; 12(1):57-65. PubMed ID: 22348551
[TBL] [Abstract][Full Text] [Related]
28. Gene therapy for primary immunodeficiencies.
Fox TA; Booth C
Br J Haematol; 2021 Jun; 193(6):1044-1059. PubMed ID: 33336808
[TBL] [Abstract][Full Text] [Related]
29. Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.
Aiuti A; Brigida I; Ferrua F; Cappelli B; Chiesa R; Marktel S; Roncarolo MG
Immunol Res; 2009; 44(1-3):150-9. PubMed ID: 19224139
[TBL] [Abstract][Full Text] [Related]
30. Gene therapy for primary immunodeficiencies.
Fischer A; Hacein-Bey Abina S; Touzot F; Cavazzana M
Clin Genet; 2015 Dec; 88(6):507-15. PubMed ID: 25708106
[TBL] [Abstract][Full Text] [Related]
31. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
[TBL] [Abstract][Full Text] [Related]
32. Gene Therapy for Inborn Errors of Immunity: Severe Combined Immunodeficiencies.
Chetty K; Houghton BC; Booth C
Hematol Oncol Clin North Am; 2022 Aug; 36(4):813-827. PubMed ID: 35773051
[TBL] [Abstract][Full Text] [Related]
33. Evolving Gene Therapy in Primary Immunodeficiency.
Thrasher AJ; Williams DA
Mol Ther; 2017 May; 25(5):1132-1141. PubMed ID: 28366768
[TBL] [Abstract][Full Text] [Related]
34. Gene therapy and genome editing for primary immunodeficiency diseases.
Zhang ZY; Thrasher AJ; Zhang F
Genes Dis; 2020 Mar; 7(1):38-51. PubMed ID: 32181274
[TBL] [Abstract][Full Text] [Related]
35. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.
Wu C; Dunbar CE
Front Med; 2011 Dec; 5(4):356-71. PubMed ID: 22198747
[TBL] [Abstract][Full Text] [Related]
36. Treatment of an infant with X-linked severe combined immunodeficiency (SCID-X1) by gene therapy in Australia.
Ginn SL; Curtin JA; Kramer B; Smyth CM; Wong M; Kakakios A; McCowage GB; Watson D; Alexander SI; Latham M; Cunningham SC; Zheng M; Hobson L; Rowe PB; Fischer A; Cavazzana-Calvo M; Hacein-Bey-Abina S; Alexander IE
Med J Aust; 2005 May; 182(9):458-63. PubMed ID: 15865589
[TBL] [Abstract][Full Text] [Related]
37. New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy.
Sauer AV; Aiuti A
Curr Opin Allergy Clin Immunol; 2009 Dec; 9(6):496-502. PubMed ID: 19779332
[TBL] [Abstract][Full Text] [Related]
38. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
[TBL] [Abstract][Full Text] [Related]
39. Genotoxicity of retroviral hematopoietic stem cell gene therapy.
Trobridge GD
Expert Opin Biol Ther; 2011 May; 11(5):581-93. PubMed ID: 21375467
[TBL] [Abstract][Full Text] [Related]
40. Advances in gene therapy for ADA-deficient SCID.
Aiuti A
Curr Opin Mol Ther; 2002 Oct; 4(5):515-22. PubMed ID: 12435054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]